Energy disaggregation, also known as non-intrusive load monitoring (NILM), challenges the problem of separating the whole-home electricity usage into appliance-specific individual consumptions, which is a typical application of data analysis. NILM aims to help households understand how the energy is used and consequently tell them how to effectively manage the energy, thus allowing energy efficiency, which is considered as one of the twin pillars of sustainable energy policy (i.e., energy efficiency and renewable energy). Although NILM is unidentifiable, it is widely believed that the NILM problem can be addressed by data science. Most of the existing approaches address the energy disaggregation problem by conventional techniques such as sparse coding, non-negative matrix factorization, and the hidden Markov model. Recent advances reveal that deep neural networks (DNNs) can get favorable performance for NILM since DNNs can inherently learn the discriminative signatures of the different appliances. In this article, we propose a novel method named adversarial energy disaggregation based on DNNs. We introduce the idea of adversarial learning into NILM, which is new for the energy disaggregation task. Our method trains a generator and multiple discriminators via an adversarial fashion. The proposed method not only learns shared representations for different appliances but captures the specific multimode structures of each appliance. Extensive experiments on real-world datasets verify that our method can achieve new state-of-the-art performance.

No abstract

medians (70%, 95% CI 65-74%) than those in 2012 (50%, 95% CI 46-56%). There was a significant relationship between age and adherence, with older subjects having a higher median PDC (4% more for 10 years difference). Conclusions: A recent analysis suggests that drug levels consistent with ‡ 4 TVD pills/wk resulted in a HIV risk reduction of 86-100%. Overall adherence to TVD for PrEP in this retail data base population is consistent with levels that have shown significant reduction in HIV transmission in clinical trials. This is the first assessment of adherence to PrEP among individuals outside of a clinical trial setting. Novel Vaccine ConceptsOA16.01